Business Context and Reporting Period
Company: Biorestorative Therapies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 27, 2018
Reporting Period: Events occurring between May 14, 2018, and June 29, 2018.
Key Financial Metrics and Capital Activities
This filing reports specific unregistered sales of equity securities and debt issuances rather than standard operating financial metrics (revenue, profit, cash flow). Key capital activity figures include:
- Debt-for-Equity Swap: Issued 179,499 shares of common stock to settle $198,780 of outstanding indebtedness (including accrued interest).
- Loan Extension Compensation: Issued 10,000 shares of common stock (fair value approx. $20,000) to lenders in exchange for extending loan maturity dates.
- New Debt Issuance: Issued promissory notes with an aggregate principal amount of $315,000.
- Conversion Terms: New notes are convertible at $2.00 per share at the holder's election.
Material Changes Versus Prior Period
The filing does not provide comparative financial data (e.g., revenue or net income) against prior periods. The material changes reported are strictly related to capital structure adjustments:
- Reduction of outstanding indebtedness by $198,780 through equity issuance.
- Extension of maturity dates for certain existing loans.
- Accretion of new debt obligations totaling $315,000.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, revenue outlook, or strategic commentary beyond the description of the transactions.
Risks and Contingencies:
- Regulatory Compliance: The Company relied on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933 for exemptions from registration.
- Investor Status: The Company reasonably believes all investors are accredited; no general solicitation was used.
- Dilution Risk: The issuance of 189,499 total shares and the creation of convertible debt may dilute existing shareholders.
Important Facts for Investor Verification
- Verify the total number of shares outstanding post-transaction to assess dilution impact.
- Confirm the remaining balance of the $315,000 in newly issued convertible notes and their maturity dates.
- Review the Company's cash position to determine if the debt-for-equity swap was necessary due to liquidity constraints.
- Check subsequent filings for any default events on the extended loans or new notes.